专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09107936B2 Antagonists of GRASP55 for use as a medicament 有权
标题翻译： GRASP55拮抗剂用作药物
公开(公告)号：US09107936B2
公开(公告)日：2015-08-18
申请号：US13983417
申请日：2012-02-02
申请人： Michel Aurrand-Lions , Ana Zarubica
发明人： Michel Aurrand-Lions , Ana Zarubica
IPC分类号： C12N15/11 , A61K31/713 , C07K14/47 , C12N15/113 , A61K39/395 , C07H21/04
CPC分类号： A61K31/713 , A61K39/3955 , C07K14/47 , C12N15/113 , C12N2310/14 , C12N2310/531
摘要： The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases.
摘要翻译：本发明涉及55kDa（Grasp55）的高尔基重组 - 堆叠蛋白的拮抗剂，用作药物，特别是用于治疗涉及疾病的细胞粘附分子，特别是涉及MCAM或JAM的疾病。根据一些实施方案，55kDa（Grasp55）的高尔基重组 - 堆叠蛋白的所述拮抗剂可用于治疗癌症，转移和炎性疾病。本发明还提供了筛选易于治疗或预防这些疾病的化合物的方法。

2. 发明授权

US08007797B2 Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use 有权
标题翻译：功能粘附分子-C（JAM-C）结合化合物及其使用方法
公开(公告)号：US08007797B2
公开(公告)日：2011-08-30
申请号：US12443231
申请日：2007-09-28
申请人： Pierre-Yves Dietrich , Mirna Tenan , Michel Aurrand-Lions , Beat Albert Imhof
发明人： Pierre-Yves Dietrich , Mirna Tenan , Michel Aurrand-Lions , Beat Albert Imhof
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , C07K2317/92
摘要： The present invention relates to the use of a compound that specifically binds to JAM-C or JAM-B for the treatment of gliomas. More specifically the invention relates to the use of an antagonist of JAM-B or JAM-C for the treatment of glioma, in particular astrocytoma.
摘要翻译：本发明涉及特异性结合JAM-C或JAM-B用于治疗神经胶质瘤的化合物的用途。更具体地，本发明涉及JAM-B或JAM-C拮抗剂用于治疗胶质瘤，特别是星形细胞瘤的用途。

3. 发明授权

US07790863B2 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer 有权
标题翻译：血管生成抑制分子及其在治疗和诊断癌症中的应用
公开(公告)号：US07790863B2
公开(公告)日：2010-09-07
申请号：US10579105
申请日：2004-11-19
申请人： Beat A. Imhof , Michel Aurrand-Lions
发明人： Beat A. Imhof , Michel Aurrand-Lions
IPC分类号： C07K16/28 , A61K39/395 , G01N33/53 , G01N33/577 , C12P21/08 , C12N5/20
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2803 , C07K2317/76 , G01N33/566 , G01N2333/705
摘要： The present invention relates to angiogenesis inhibiting molecules that are the monoclonal antibody H33 or fragments or derivatives thereof, to their use in the treatment of cancer, in particular the treatment of solid tumors and to therapeutic and diagnostic compositions comprising them. The invention relates in particular to humanized derivatives of H33 of human monoclonal antibodies having the specificity of H33.
摘要翻译：本发明涉及血管生成抑制分子，其是单克隆抗体H33或其片段或衍生物，用于治疗癌症，特别是治疗实体瘤以及包含它们的治疗和诊断组合物。本发明特别涉及具有H33特异性的人单克隆抗体的H33人源化衍生物。

4. 发明申请

US20080274970A1 VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION 有权
标题翻译：血管粘连分子及其功能调节
公开(公告)号：US20080274970A1
公开(公告)日：2008-11-06
申请号：US12137898
申请日：2008-06-12
申请人： Beat Albert Imhof , Michel Aurrand-Lions
发明人： Beat Albert Imhof , Michel Aurrand-Lions
IPC分类号： A61K38/16 , C07K16/00 , C07H21/00 , A61P35/00 , C12N5/06
CPC分类号： C07K14/70503 , Y02P20/582
摘要： The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. 3, upper and second row, respectively, and antibodies thereto as well as their use in treatment of inflammation and tumors.
摘要翻译：本发明涉及属于人免疫球蛋白超家族亚科的分离形式的新多肽，该多肽与鼠融合调节粘附分子1或2（CRAM-1或CRAM-1）的氨基酸序列具有至少70％的序列同源性， 2），如图2所示。 3，上，第2排及其抗体，以及它们在治疗炎症和肿瘤中的用途。

5. 发明申请

US20130309252A1 ANTAGONISTS OF GRASP55 FOR USE AS A MEDICAMENT 有权
标题翻译： GRASP55作为药物使用的拮抗剂
公开(公告)号：US20130309252A1
公开(公告)日：2013-11-21
申请号：US13983417
申请日：2012-02-02
申请人： Michel Aurrand-Lions , Ana Zarubica
发明人： Michel Aurrand-Lions , Ana Zarubica
IPC分类号： A61K31/713 , A61K39/395
CPC分类号： A61K31/713 , A61K39/3955 , C07K14/47 , C12N15/113 , C12N2310/14 , C12N2310/531
摘要： The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases.
摘要翻译：本发明涉及55kDa（Grasp55）的高尔基重组 - 堆叠蛋白的拮抗剂，用作药物，特别是用于治疗涉及疾病的细胞粘附分子，特别是涉及MCAM或JAM的疾病。根据一些实施方案，55kDa（Grasp55）的高尔基重组 - 堆叠蛋白的所述拮抗剂可用于治疗癌症，转移和炎性疾病。本发明还提供了筛选易于治疗或预防这些疾病的化合物的方法。

6. 发明申请

US20100267649A1 VASCULAR ADHESION MOLECULES AND MODULATION OF THEIR FUNCTION 有权
标题翻译：血管粘连分子及其功能调节
公开(公告)号：US20100267649A1
公开(公告)日：2010-10-21
申请号：US12703439
申请日：2010-02-10
申请人： Beat Albert Imhof , Michel Aurrand-Lions
发明人： Beat Albert Imhof , Michel Aurrand-Lions
IPC分类号： A61K38/17 , C07K16/18 , A61P43/00
CPC分类号： C07K14/70503 , Y02P20/582
摘要： The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. 3, upper and second row, respectively, and antibodies thereto as well as their use in treatment of inflammation and tumors.
摘要翻译：本发明涉及属于人免疫球蛋白超家族亚科的分离形式的新多肽，该多肽与鼠融合调节粘附分子1或2（CRAM-1或CRAM-1）的氨基酸序列具有至少70％的序列同源性， 2），如图2所示。 3，上，第2排及其抗体，以及它们在治疗炎症和肿瘤中的用途。

7. 发明授权

US07670826B2 Confluence regulated adhesion molecules useful in modulating vascular permeability 有权
标题翻译：汇合调节粘附分子可用于调节血管通透性
公开(公告)号：US07670826B2
公开(公告)日：2010-03-02
申请号：US12137898
申请日：2008-06-12
申请人： Beat Albert Imhof , Michel Aurrand-Lions
发明人： Beat Albert Imhof , Michel Aurrand-Lions
IPC分类号： C12N1/20 , C07H21/04 , C12P21/06 , C12N15/87
CPC分类号： C07K14/70503 , Y02P20/582
摘要： The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. 3, upper and second row, respectively, and antibodies thereto as well as their use in treatment of inflammation and tumors.
摘要翻译：本发明涉及属于人免疫球蛋白超家族亚科的分离形式的新多肽，该多肽与鼠融合调节粘附分子1或2（CRAM-1或CRAM-1）的氨基酸序列具有至少70％的序列同源性， 2），如图2所示。 3，上，第2排及其抗体，以及它们在治疗炎症和肿瘤中的用途。

8. 发明授权

US07642341B2 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer 有权
标题翻译：血管发生抑制分子，其选择，产生及其在治疗癌症中的应用
公开(公告)号：US07642341B2
公开(公告)日：2010-01-05
申请号：US10738123
申请日：2003-12-18
申请人： Beat A. Imhof , Michel Aurrand-Lions
发明人： Beat A. Imhof , Michel Aurrand-Lions
IPC分类号： C07K16/28 , C12N5/20 , C12P21/08 , G01N33/53 , G01N33/577
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/73
摘要： The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular MAb H33, to soluble JAM-C and JAM-B and to small molecules.
摘要翻译：本发明涉及提供能够抑制血管发生的分子的方法，包括提供一系列分子的步骤; 测试这些分子是否能够阻止JAM-B和JAM-C之间的相互作用; 测试阳性分子在体内阻断血管发生的能力; 并在血管生成试验中选择阳性的分子作为血管生成抑制分子。该方法还可以包括分离或产生抑制血管生成的分子的步骤。本发明还涉及由此提供和产生的用于治疗癌症的血管生成抑制分子用于包含它们的治疗组合物。在一个具体实施方案中，本发明涉及单克隆抗体，特别是涉及可溶性JAM-C和JAM-B以及小分子的单克隆抗体，特别是MAb H33。

9. 发明授权

US08143056B2 Vascular adhesion molecules and modulation of their function 有权
标题翻译：血管粘附分子及其功能调节
公开(公告)号：US08143056B2
公开(公告)日：2012-03-27
申请号：US12703439
申请日：2010-02-10
申请人： Beat Albert Imhof , Michel Aurrand-Lions
发明人： Beat Albert Imhof , Michel Aurrand-Lions
IPC分类号： C07K16/00 , C07K16/28 , C12N5/20
CPC分类号： C07K14/70503 , Y02P20/582
摘要： The invention relates to new polypeptides in isolated form belonging to a subfamily of the human immunoglobulin superfamily, which polypeptide shows at least 70% sequence homology with the amino acid sequence of the murine Confluency Regulated Adhesion Molecules 1 or 2 (CRAM-1 or CRAM-2) as depicted in FIG. 3, upper and second row, respectively, and antibodies thereto as well as their use in treatment of inflammation and tumors.
摘要翻译：本发明涉及属于人免疫球蛋白超家族亚科的分离形式的新多肽，该多肽与鼠融合调节粘附分子1或2（CRAM-1或CRAM-1）的氨基酸序列具有至少70％的序列同源性， 2），如图2所示。 3，上，第2排及其抗体，以及它们在治疗炎症和肿瘤中的用途。

10. 发明授权

US08093010B2 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer 有权
标题翻译：血管发生抑制分子，其选择，产生及其在治疗癌症中的应用
公开(公告)号：US08093010B2
公开(公告)日：2012-01-10
申请号：US12608029
申请日：2009-10-29
申请人： Beat A. Imhof , Michel Aurrand-Lions
发明人： Beat A. Imhof , Michel Aurrand-Lions
IPC分类号： G01N33/53 , G01N33/536 , G01N33/543 , G01N33/567 , G01N33/577 , C07K16/28 , C12N5/20
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/73
摘要： The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.
摘要翻译：本发明涉及提供能够抑制血管发生的分子的方法，包括提供一系列分子的步骤; 测试这些分子是否能够阻止JAM-B和JAM-C之间的相互作用; 测试阳性分子在体内阻断血管发生的能力; 并在血管生成试验中选择阳性的分子作为血管生成抑制分子。该方法还可以包括分离或产生抑制血管生成的分子的步骤。本发明还涉及由此提供和产生的用于治疗癌症的血管生成抑制分子用于包含它们的治疗组合物。在一个具体实施方案中，本发明涉及单克隆抗体，特别是涉及可溶性JAM-C和JAM-B以及小分子的单克隆抗体，特别是Mab H33。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式